Free Trial

Global Blood Therapeutics (GBT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
74 shs
Average Volume
2.07 million shs
Market Capitalization
$4.62 billion
P/E Ratio
Dividend Yield
Price Target
GBT stock logo

About Global Blood Therapeutics Stock (NASDAQ:GBT)

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

GBT Stock News Headlines

Amex GBT to Acquire CWT for $570 Million
Should we pay people for donating blood?
GBT Technologies Cancels and Voids Reverse Stock Split
PFE Mar 2024 32.500 call
The Global Non-insulin Diabetes Therapeutics Market
See More Headlines
Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical Preparations
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$194.75 million
Book Value
$3.05 per share


Free Float
Market Cap
$4.62 billion
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Ted W. Love M.D. (Age 63)
    Pres, CEO & Director
    Comp: $1.06M
  • Mr. Jeffrey S. Farrow (Age 60)
    CFO & Principal Accounting Officer
    Comp: $672.67k
  • Ms. Jung E. Choi (Age 52)
    Chief Bus. & Strategy Officer
    Comp: $645k
  • Mr. David L. Johnson (Age 53)
    Chief Commercial Officer
    Comp: $661.5k
  • Dr. Kim Smith-Whitley M.D. (Age 61)
    Exec. VP and Head of R&D
    Comp: $654k
  • Dr. David R. Phillips
    Founder & Advisor
  • Dr. Matthew P. Jacobson Ph.D.
    Founder & Advisor
  • Dr. Andrej Sali Ph.D.
    Founder & Advisor
  • Ms. Nazila Habibizad (Age 59)
    Exec. VP of Operations
  • Stephanie Yao
    Sr. Director of Corp. Communications & Investor Relations

GBT Stock Analysis - Frequently Asked Questions

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($1.13) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by $0.03. The business had revenue of $52.05 million for the quarter, compared to analyst estimates of $53.69 million. Global Blood Therapeutics had a negative trailing twelve-month return on equity of 170.37% and a negative net margin of 137.30%. The firm's quarterly revenue was up 41.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.97) earnings per share.

What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?

20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ).

When did Global Blood Therapeutics IPO?

Global Blood Therapeutics (GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

This page (NASDAQ:GBT) was last updated on 6/12/2024 by Staff

From Our Partners